



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Siegfried ANSORGE et al.

Confirmation No.: 4700

Serial No. : 10/575,882

Group Art Unit: 1632

(National Stage of PCT/EP2004/011643)

Examiner: not yet assigned

I. A. Filed: October 15, 2004

For

NON 3 0 5008

: NOVEL ALANYL-AMINO PEPTIDASE INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98, Applicants hereby direct the Examiner's attention to the following documents cited in the International Search Report for International Application PCT/EP2004/011643, of which the above-referenced application is a National Stage:

- (1) WO 01/89569 A1, November 29, 2001; Applicants note that this document is cited and discussed, beginning at page 1, line 18 of the present application;
- (2) U.S. Patent Application Publication No. 2005/0014699 A1 (ANSORGE et al.), January 20, 2005; Applicants note that this document is a family member of document (1);

- (3) Database Beilstein XP-002320599, database accession no. 7444296,Chemical Name actinonin; and references cited therein;
- (4) Database Beilstein XP-002320600, database accession no. 2121406, and references cited therein;
- (5) Abstract of ECKSTEIN Z. et al. "The fungistatic activity of 3,4-dichlorophenoxyacethydroxamic acid on pathogenic fungi in vitro" Bull. acad. polon. sci. ser. sci., chim., geol. et geopraph., 1958, (6), pp. 235-238 (abstract retrieved from STN);
- (6) Abstract of ALK'EWICZ J. et al. "Fungistatic activity of some hydroxamic acids" Nature, vol. 180, 1957, pp. 1204-1205 (abstract retrieved from STN).

Applicants further direct the Examiner's attention to the following documents cited and discussed in the present application:

- (7) LENDECKEL U. et al. "Role of alanyl aminopeptidase in growth and function of human T cells (Review)", International Journal of Molecular Medicine, vol. 4, 1999, pp. 17-27; Applicants note that this document is cited and discussed at page 1, line 17 of the present application;
- (8) KONTOYIANNIS D. P. et al. "Aminopeptidase N inhibitors and SARS", The Lancet, vol. 361, 2003, p. 1558; Applicants note that this document is cited and discussed, beginning at page 1, line 28 of the present application;

- (9) FOURNIÉ-ZALUSKI et al. "New Selective Aminopeptidase N Inhibtors as Potential Therapeutics" in J. Langner and S. Ansorge, "Ectopeptidase", Kluwer Academic/Plenum Publisher, 2002, pp. 51-94; Applicants note that this document is cited and discussed, beginning at page 2, line 1 of the present application;
- (10) KOMODA M. et al. "Specific Inhibitor of Puromycin-Sensitive Aminopeptidase with a Homophthalimide Skeleton: Identification of the Target Molecule and a Structure-Activity Relationship Study", Bioorganic & Medicinal Chemistry, vol. 9, 2001, pp. 121-131; Applicants note that this document is cited and discussed, beginning at page 1, line 15 of the present application;
- (11) HASHIMOTO Y. "Structural Development of Biological Response Modifiers Based on Thalidomide" Bioorganic & Medicinal Chemistry, vol. 10, 2002, pp. 461-479; Applicants note that this document is cited and discussed, beginning at page 2, line 4 of the present application;
- (12) BARRETT A. J. et al. Membrane "Alanyl aminopeptidase" and "Aminopeptidase PS" in "Handbook of Proteolytic Enzymes", Academic Press, 1998; Applicants note that this document is cited and discussed, beginning at page 1, line 11 of the present application;
- (13) WO 02/053170 A2, July 11, 2002; Applicants note that this document is cited and discussed, beginning at page 1, line 21 the present application;

- (14) WO 2004/004750 A2, January 15, 2004; Applicants note that this document is cited and discussed, beginning at page 1, line 22 of the present application;
- (15) U.S. Patent Application Publication No. 2006/0211602 A1 (ANSORGE et al.), September 21, 2006; Applicants note that this document is a family member of document (14);
- (16) WO 02/053169 A2, July 11, 2002; Applicants note that this document is cited and discussed, beginning at page 1, line 23 of the present application;
- (17) U.S. Patent Application Publication No. 2004/0147434 A1 (ANSORGE et al.), July 29, 2004; Applicants note that this document is a family member of document (16);
- (18) DE 103 37 074 A1, March 17, 2005; Applicants note that this document is cited and discussed, beginning at page 1, line 23 of the present application;
- (19) U.S. Patent Application Publication No. 2005/0113310 A1 (STRIGGOW et al.), May 26, 2005; Applicants note that this document is a family member of document (18);
- (20) DE 103 30 842 A1, February 10, 2005, accompanied by an English language abstract thereof (provided by esp@cenet); Applicants note that this document is cited and discussed, beginning at page 2, line 13 of the present application;

- (21) WO 03/077935 A1, September 25, 2003; Applicants note that this document is cited and discussed, beginning at page 1, line 26 of the present application;
- (22) U.S. Patent Application Publication No. 2006/0040850 A1 (ANSORGE et al.), February 23, 2006; Applicants note that this document is a family member of document (21);
- (23) DD 296 075 A5, November 21, 1991; Applicants note that this document is cited and discussed, beginning at page 14, line 27 of the present application.

Furthermore, Applicants direct the Examiner to the following copending and commonly assigned applications:

- (24)U.S. Patent Application No. 10/575,883 to ANSORGE et al. filed April 14, 2006 and entitled "NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL. INFLAMMATORY, NEURONAL, AND OTHER DISEASES"; Applicants note that this document is a national stage of International Application PCT/EP2004/011645;
- (25) U.S. Patent Application No. 10/575,878 to ANSORGE et al. filed April 14, 2006 and entitled "DUAL ALANYL AMINOPEPTIDASE AND DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND FOR TREATING

IMMUNOLOGICAL, INFLAMMATORY, NEURONAL AND OTHER DISEASES"; Applicants note that this document is a national stage of International Application PCT/EP2004/011644.

Applicants further direct the Examiner's attention to the following documents that were made of record in above-listed copending and commonly assigned applications (24) and (25):

- (26) BUGNI T. et al. "p-Sulfooxyphenylpyruvic acid from the red macro alga Ceratodictyon spongiosum and its sponge symbiont Haliclona cymaeformis", Phytochemistry, vol. 60, no. 4, 2002, pp. 361-363;
- (27) OGATA M. et al. "Synthesis and Antifungal Activity of a Series of Novel 1,2-Disubstituted Propenones", Journal of Medicinal Chemistry, vol. 30, 1987, pp. 1497-1502;
- Derived from *N*-Boc-Iminodiacetic Acid: Solution-Phase Synthesis of Piperazinone Libraries with Activity Against LEF-1/β-Catenin-Mediated Transcription", Helvetica Chimica Acta, vol. 83, 2000, pp. 1825-1845;
- (29) MITTAL S. et al. "Structure-Activity Relationship of Estrogens: Receptor Affinity and Estrogen Antagonist Activity of Certain (*E*)- and (*Z*)-1,2,3-Triaryl-2-propen-1-ones", Journal of Medicinal Chemistry, vol. 28, 1985, pp. 492-497;
- (30) CUSHMAN M. et al. "Synthesis and Evaluation of Analogues of (*Z*)-1- (4-Methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene as Potential

- Cytotoxic and Antimitotic Agents", Journal of Medicinal Chemistry, vol. 35, 1992, pp. 2293-2306;
- (31) ASTLES P. C. et al. "Selective Endothelin A Receptor Antagonists. 4.

 Discovery and Structure-Activity Relationships of Stilbene Acid and Alcohol Derivatives", Journal of Medicinal Chemistry, vol. 41, 1998, pp. 2745-2753;
- (32) MEANWELL N. A. et al. "Nonprostanoid Prostacyclin Mimetics. 4. Derivatives of 2-[3-[2-(4,5-Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic Acid Substituted α to the Oxazole Ring", Journal of Medicinal Chemistry, vol. 36, 1993, pp. 3871-3883;
- (33) AUGUSTYNS K. et al "The Unique Properties of Dipeptidyl-peptidase IV (DPP IV / CD26) and the Therapeutic Potential of DPP IV Inhibitors", Current Medicinal Chemistry, vol. 6, no. 4, 1999, pp 311-327;
- (34) CHEN T. et al. "Dipeptidyl Peptidase IV Gene Family", Adv. Exp. Med. Biol., vol. 524, 2003, pp 79-86;
- (35) DUKE-COHAN J.S. et al. "Serum High Molecular Weight Dipeptidyl Peptidase IV (CD26) is Similar to a Novel Antigen DPPT-L Released from Activated T Cells", The Journal of Immunology, vol. 156, 1996, pp. 1714-1721;
- (36) KÄHNE T. et al. "Dipeptidyl peptidase IV: A cell surface peptidase involved in regulating T cell growth (Review)", International Journal of Molecular Medicine, vol. 4, 1999, pp. 3-15;

- (37) DE MEESTER I. et al. "Dipeptidyl Peptidase IV Substrates", Adv. Exp. Med. Biol., vol. 524 (2002), pp. 3-17;
- (38) EVANS D. M. "Dipeptidyl Peptidase IV Inhibitors", IDrugs, vol. 5, no. 6, 2002, pp. 577-585;
- (39) DE 101 55 093 A1, June 12, 2003; Applicants note that this document is a family member of document (13);
- (40) U.S. Patent Application Publication No. 2004/0132639 A1 (ANSORGE et al.), July 8, 2004; Applicants note that this document is a family member of document (39) and (13);
- (41) U.S. Patent Application Publication No. 2002/0198205 A1 (HIMMELSBACH et al.), December 26, 2002;
- (42) WO 2004/041820 A1, May 21, 2004;
- (43) U.S. Patent Application Publication No. 2004/0138214 A1 (HIMMELSBACH et al.), July 15, 2004; Applicants note that this document is a family member of document (42);
- (44) WO 03/035067 A1, May 1, 2003;
- (45) U.S. Patent Application Publication No. 2005/0004205 A1 (EVANS et al.), January 6, 2005; Applicants note that this document is a family member of document (44);
- (46) WO 03/045977 A2, June 5, 2003;
- (47) U.S. Patent Application Publication No. 2005/0070482 A1 (BACHOVCHIN), March 31, 2005; Applicants note that this document is a family member of document (46).

Copies of the above-listed documents (with the exception of U.S. patent applications), the International Search Report and the International Preliminary Report on Patentability (English language translation) for International Application PCT/EP2004/011643 are enclosed together with a completed copy of the Form PTO-1449 listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the Form PTO-1449 with the next official communication.

Further to the U.S. Patent and Trademark Office's decision to waive the requirement under 37 C.F.R. §1.98 (a)(2)(iii) if a U.S. patent application was filed after June 30, 2003, copies of the U.S. patent applications cited above are not enclosed herewith. However, if any copies are needed, the Examiner is respectfully requested to contact the undersigned.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

Should there be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted, Siegfried ANSORGE et al.

Neil F. Greenblum Reg. No. 28,394

November 7, 2006 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191

Heribert F. Muensterer Reg. No. 50,417 FORM PTO-1449

0.5. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

(Use several sheets if necessary)

Atty. Docket No. P29677

Application No 10/575,882

Applicant

Siegfried ANSORGE et al.

Filing Date April 14, 2006 Group 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	2005 /	0	0	1	4	6	9	9	01/20/05	ANSORGE et al.				
	2006 /	0	2	1	1	6	0	2	09/21/06	ANSORGE et al.				
	2004 /	0	_1	4	7	4	3	4	07/29/04	ANSORGE et al.				
	2005 /	0	1	1	3	3	1	0	05/26/05	STRIGGOW et al.				
	2004 /	0	1	3	2	6	3	9	07/08/04	ANSORGE et al.				
	2002 /	0	1	9	8	2	0	5	12/26/02	HIMMELSBACH et al.				
	2004 /	0	1	3	8	2	1	4	07/15/04	HIMMELSBACH et al.				
	2006 /	0	0	4	0	8	5	0	02/23/06	ANSORGE et al.			(
	2005 /	0	0	7	0	4	8	2	03/31/05	BACHOVCHIN				
	2005/	0	0	0	4	2	O	5	01/06/05	EVANS et al.				

FOREIGN PATENT DOCUMENTS

		DO	CUM	ENT	NUM	BER		DATE	COUNTRY	CLASS	SUB CLA SS	TRANSL YES	ATION NO
 0	1	1	8	9	5	6	9	11/29/01	W.I.P.O.	-			
 02	1	0	5	3	1	7	0	07/11/02	W.I.P.O.				
2004	7	0	0	4	7	5	0	01/15/04	W.I.P.O.				
 02	1	0	5	3	1	6	9	07/11/02	W.I.P.O.				
1	0	3	3	7	Ó	7	4	03/17/05	GERMANY				
1	0	3	3	0	8	4	2	02/10/05	GERMANY				
03	1	0	7	7	9	3	5	09/25/03	W.I.P.O.				
		2	9	6	0	7	5	11/21/91	GERMANY DEMOCRATIC REPUBL	IC			
1	0	1	5	5	0	9	3	06/12/03	GERMANY				
 03	1	0	4	5	9	7	7	06/05/03	W.I.P.O.				
2004	1	0	4	1	8	2	0	05/21/04	W.I.P.O.				
03	1	0	3	5	0	6	7,.	05/01/03	W.I.P.O.				
 						01111	ENT	0 " 1 " 4	other Title Date Destinant Danie Cf	- 1	•		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

·	-1	Database Beilstein XP-002320599, database accession no. 7444296, Chemical Name actinonin.
	2	Database Beilstein XP-002320600, database accession no. 2121406, and references cited therein.
	3	Abstract of ECKSTEIN Z. et al. "The fungistatic activity of 3,4-dichlorophenoxyacethydroxamic acid on pathogenic fungi in vitro" Bull. acad. polon. sci. ser. sci., chim., geol. et geopraph., 1958, (6), pp. 235-238 (abstract retrieved from STN).
	4	Abstract of ALK'EWICZ J. et al. "Fungistatic activity of some hydroxamic acids" Nature, vol. 180, 1957, pp. 1204-1205 (abstract retrieved from STN)

(Review)", International Journal of Molecular Medicine, vol. 4, 1999, pp. 17-27.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LENDECKEL U. et al. "Role of alanyl aminopeptidase in growth and function of human T cells

5

FORM PTO-1	1449	Patent and Trademark Office	Atty. Docker	Application No. 10/575,882					
II.	NFORM	ATION DISCLOSURE STATEMENT	Applicant Siegfried ANSORGE et al.	33.07.01002					
	(Us	BY APPLICANT se several sheets if necessary)	Filing Date April 14, 2006	Group 1632					
		OTHER DOCUMENTS (Including Author, Title,	Date, Pertinent Pages, Etc.)						
	6	KONTOYIANNIS D. P. et al. "Aminopeptidase N p. 1558.	I inhibitors and SARS", The	Lancet, vol. 361, 2003,					
	7	FOURNIÉ-ZALUSKI et al. "New Selective Amino J. Langner and S. Ansorge, "Ectopeptidase", Klu	ppeptidase N Inhibtors as Po wer Academic/Plenum Publ	er Academic/Plenum Publisher, 2002, pp. 51-94.					
	8	KOMODA M. et al. "Specific Inhibitor of Puromycin-Sensitive Aminopeptidase with Homophthalimide Skeleton: Identification of the Target Molecule and a Structure-Ac Relationship Study", Bioorganic & Medicinal Chemistry, vol. 9, 2001, pp. 121-131.							
	9	HASHIMOTO Y. "Structural Development of Bio Bioorganic & Medicinal Chemistry, vol. 10, 2002	at Chemistry, vol. 10, 2002, pp. 461-479.						
	10	BARRETT A. J. et al. Membrane "Alanyl amino of Proteolytic Enzymes", Academic Press, 1998.	peptidase" and "Aminopeption	dase PS" in "Handbook					
·	11	U.S. Patent Application No. 10/575,883 to ANSORGE et al. filed April 14, 2006 and entitle "NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCIN DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AN OTHER DISEASES".							
	12	U.S. Patent Application No. 10/575,878 to ANSORGE et al. filed April 14, 2006 and entitled "DUAL ALANYL AMINOPEPTIDASE AND DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND FOR TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL AND OTHER DISEASES.							
	13	BUGNI T. et al. "p-Sulfooxyphenylpyruvic acid f and its sponge symbiont Haliclona cymaeformis"	rom the red macro alga <i>Cer</i> , Phytochemistry, vol. 60, no	ratodictyon spongiosum o. 4, 2002, pp. 361-363.					
	14	OGATA M. et al. "Synthesis and Antifungal Propenones", Journal of Medicinal Chemistry, vo		Novel 1,2-Disubstituted					
	15	BOGER D. L. et al. "Non-Amide-Based Combinatorial Libraries Derived from <i>N</i> -Boc-Iminodial Acid: Solution-Phase Synthesis of Piperazinone Libraries with Activity Against LEF-1/β-Cate Mediated Transcription", Helvetica Chimica Acta, vol. 83, 2000, pp. 1825-1845.							
	16	MITTAL S. et al. "Structure-Activity Relationsl Antagonist Activity of Certain (<i>E</i>)- and (<i>Z</i>)-1,2 Chemistry, vol. 28, 1985, pp. 492-497.	nip of Estrogens: Receptor 2,3-Triaryl-2-propen-1-ones"	Affinity and Estrogen Journal of Medicinal					
	17	CUSHMAN M. et al. "Synthesis and Evaluation of Analogues of (<i>Z</i>)-1-(4-Methoxyphenyl)-2-(3, trimethoxyphenyl)ethene as Potential Cytotoxic and Antimitotic Agents", Journal of Medic Chemistry, vol. 35, 1992, pp. 2293-2306.							
	18	ASTLES P. C. et al. "Selective Endothelin A Receptor Antagonists. 4. Discovery and Structure-Activity Relationships of Stilbene Acid and Alcohol Derivatives", Journal of Medicinal Chemistry, vol. 41, 1998, pp. 2745-2753.							
	19	MEANWELL N. A. et al. "Nonprostanoid Prostacyclin Mimetics. 4. Derivatives of 2-[3-[2-(4,5 Diphenyl-2-oxazolyl)ethyl]phenoxy]acetic Acid Substituted α to the Oxazole Ring", Journal o Medicinal Chemistry, vol. 36, 1993, pp. 3871-3883.							
	20	AUGUSTYNS K. et al "The Unique Properties of Dipeptidyl-peptidase IV (DPP IV / CD26) and the Therapeutic Potential of DPP IV Inhibitors", Current Medicinal Chemistry, vol. 6, no. 4, 1999, p. 311-327.							
	21	CHEN T. et al. "Dipeptidyl Peptidase IV Gene Fa 86.	amily", Adv. Exp. Med. Biol.,	vol. 524, 2003, pp 79-					
EXAMINER		DATI	E CONSIDERED						

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

P29677.P05				Sheet 3 of
FORM PTO-	1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. P29677	Application No. 10/575,882
II.	NFORM	ATION DISCLOSURE STATEMENT	Applicant Siegfried ANSORGE et al.	
	(Us	BY APPLICANT se several sheets if necessary)	Filing Date April 14, 2006	Group 1632
		OTHER DOCUMENTS (Including Author, Title,	Date, Pertinent Pages, Etc.)	
	22	DUKE-COHAN J.S. et al. "Serum High Moleculi to a Novel Antigen DPPT-L Released from Activ 1996, pp. 1714-1721.		
	23	KÄHNE T. et al. "Dipeptidyl peptidase IV: A ogrowth (Review)", International Journal of Molec		
-	24	DE MEESTER I. et al. "Dipeptidyl Peptidase IV pp. 3-17.	Substrates", Adv. Exp. Me	d. Biol., vol. 524 (2002),
	25	EVANS D. M. "Dipeptidyl Peptidase IV Inhibitors	s", IDrugs, vol. 5, no. 6, 2002	2, pp. 577-585.
	26	English language Abstract of DE 103 30 842		
			· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·
			· ····	

EXAMINER DATE CONSIDERED *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.